ABUS’s AB-729 data on the 90mg cohort are generally consistent with the previously reported data from higher-dose and lower-dose cohorts of this trial—see #msg-155712858.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”